How the hydrolytic activity of mitochondrial ATP synthase is modulated during brown adipose tissue (BAT) thermogenesis ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

PLA was carried out using the Duolink In Situ Orange Starter Kit Mouse/Rabbit (DUO92102, Sigma-Aldrich) according to the manufacturer ... Coverslips were washed and mounted using FluorSave Reagent ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.

John Overdeck and David Siegel, who set up Two Sigma in 2001, are handing over the reins to two new co-CEOs after a years-long feud over the direction of a firm that manages $60 billion in assets ...

Two Sigma's billionaire cofounders, John Overdeck and David Siegel, are stepping down. The $60 billion quant named Carter Lyons and Scott Hoffman as the new co-CEOs. Overdeck and Siegel have made ...